Bayer's Debt Math Improves as Apollo Deal and Q2 Beat Reshape the Investment Case
Published on 08/06/2026 at 22:32 | Redaktion boerse-global.de
The calendar is doing Bayer no favours — the glyphosate settlement hearing in Missouri has slipped from August 19 to September 10 — yet the underlying financial picture keeps brightening. The German life-science group's second-quarter numbers, published Tuesday, landed ahead of consensus on the operating line, and a minority-stake sale to Apollo has pulled the debt forecast down by as much as €3 billion. The shares, trading around €49.40, have climbed roughly 33 percent since the start of the year, leaving them just over 8 percent shy of the 52-week high of €53.86 reached in recent sessions.
The Debt Story Takes a Turn
The most consequential development may be the balance sheet. By selling a minority interest in its long-acting contraceptive business to Apollo Global Management for €3.0 billion in July, Bayer has accelerated its deleveraging timeline. Management now guides for net financial debt of €29–30 billion at year-end, down from the previous €32–33 billion range. The company also tapped the dollar bond market in mid-July, placing $5.0 billion in new notes to refinance existing liabilities. For a group that has laboured under the weight of its Monsanto acquisition for years, the faster-than-expected debt reduction is a tangible sign of progress.
The operational engine is also firing more cleanly. Revenue rose 2.2 percent on a currency- and portfolio-adjusted basis to €10.872 billion, while EBITDA before special items improved 1.9 percent to €2.144 billion — a figure that beat consensus estimates by roughly 10 percent. Net income swung to a profit of €219 million from a loss of €199 million in the year-earlier quarter. Free cash flow, however, remained in negative territory at minus €371 million.
Analysts Scramble to Update Targets
The earnings beat triggered a flurry of price-target revisions. UBS lifted its target from €52.00 to €62.00 on Thursday, keeping a "Buy" rating. Goldman Sachs had already moved its target from €62.50 to €63.50 the previous day, with analyst James Quigley citing strong financial performance and pharma progress. JPMorgan raised its target to €61.00 while maintaining a neutral stance, and the DZ Bank increased its fair value from €54.00 to €60.00 with a "Buy" recommendation. Deutsche Bank held its "Buy" rating and €60.00 target, describing the quarter as "solid." Jefferies remains the outlier, keeping a "Hold" rating and nudging its target only slightly to €46.00. The resulting target range — €46.00 to €63.50 — skews clearly positive.
The Legal Calendar Shifts, Again
The postponement of the Missouri hearing stems from the laborious processing of numerous opt-out requests from plaintiffs seeking to exit the $7.25 billion settlement. The delay follows a favourable ruling for Bayer from the US Supreme Court in late June, when the justices voted 7–2 in the Durnell case, holding that federal law preempts state claims over allegedly inadequate warning labels where the EPA has granted approval. That decision strengthens Bayer's hand in the remaining opt-out litigation — and arguably explains why some plaintiffs are reconsidering their participation.
Just as Bayer works to put legal and operational risks behind it, your own business faces its own set of compliance obligations that can carry heavy penalties if overlooked. Many UK employers underestimate how vulnerable they are when key safety documents aren't in place. A free toolkit with 41 ready-to-use templates and checklists helps you document risks properly and stay on the right side of the law. Download the free Risk Assessment Toolkit
CEO Bill Anderson has used the window to push back once more against speculation of an imminent breakup of the conglomerate into its crop science, pharma and consumer health divisions, according to Handelsblatt. Instead, the company continues to reorganise at the margins: the US glyphosate business was bundled into a standalone unit called "Ruveon" in July, and Bayer filed a regulatory application in China for an additional indication of its kidney drug Kerendia.
What to Watch Next
The crop science division, which has been rolling out its AI-powered pest-monitoring platform "MagicTrap 2" across 14 additional European markets including the UK, hosts an investor event on September 2. The court hearing in Missouri follows on September 10, and third-quarter results are due November 3. For now, the legal calendar — not operational detail — is likely to set the tone, but with the debt trajectory improving and analyst targets climbing, the risk-reward calculus has shifted in ways that would have seemed improbable just a few months ago.
